20,043 Shares in Medpace Holdings, Inc. $MEDP Bought by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company acquired 20,043 Medpace shares worth approximately $10.6 million, while institutional investors collectively owned 77.98% of the company at quarter-end.
• Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 versus the $3.98 consensus and revenue of $707.33 million, up 17.2% year over year.
• Analyst sentiment remained cautious, with three Buy ratings and ten Holds and a consensus price target of $584.18; meanwhile, insiders sold approximately $81.7 million of stock over the past 90 days.

The Manufacturers Life Insurance Company acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,043 shares of the company's stock, valued at approximately $10,615,000. The Manufacturers Life Insurance Company owned about 0.07% of Medpace at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MEDP. California State Teachers Retirement System lifted its position in Medpace by 22.1% in the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company's stock worth $12,505,000 after purchasing an additional 4,719 shares during the period. BlackRock Inc. bought a new stake in Medpace in the 2nd quarter valued at $1,323,047,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Medpace in the 2nd quarter valued at $1,685,000. Local Pensions Partnership Investment Ltd raised its stake in shares of Medpace by 10.5% in the 2nd quarter. Local Pensions Partnership Investment Ltd now owns 42,000 shares of the company's stock valued at $22,265,000 after buying an additional 4,000 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of Medpace by 41.0% during the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company's stock worth $45,478,000 after acquiring an additional 23,530 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Insiders Place Their Bets

In other Medpace news, Director Fred B. Davenport, Jr. sold 7,283 shares of the business's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the transaction, the director owned 3,798 shares of the company's stock, valued at approximately $2,302,157.70. The trade was a 65.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director owned 27,825 shares in the company, valued at $16,935,129.75. The trade was a 15.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 133,821 shares of company stock worth $81,748,135. 20.50% of the stock is owned by company insiders.

Medpace Trading Down 1.8%

Shares of Medpace stock opened at $600.65 on Friday. The stock has a market capitalization of $16.77 billion, a price-to-earnings ratio of 35.21, a P/E/G ratio of 2.68 and a beta of 1.15. The firm's 50-day moving average price is $565.33 and its two-hundred day moving average price is $494.55. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace's quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and increased their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. BMO Capital Markets raised their price target on shares of Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research note on Friday, July 24th. Royal Bank Of Canada lifted their price objective on Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source